Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Completed 52Terminated 11Unknown 3Active not recruiting 3Withdrawn 2Recruiting 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 119sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89Leucovorin 86pembrolizumab 85toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Unknown × temsirolimus × Clear all
NCT01653067 2016-10-27

STORM

University Hospital Heidelberg

Phase 2 Unknown
88 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT01567930 2012-12-17

Temsirolimus as Second-line Therapy in HCC

University of Tennessee Cancer Institute

Phase 2 Unknown
25 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01246817 2012-04-11

Temsirolimus-RCC-imaging

Radboud University Medical Center

Phase 2 Unknown
51 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡